Shaping next decade of systemic therapy for head and neck squamous cell carcinoma: where do we go next?
1/5 보강
Outcomes of patients with relapsed or metastatic head and neck squamous cell carcinoma (R/M HNSCC) remain poor, despite the widespread incorporation of immune checkpoint inhibitors into contemporary t
APA
Saerens M, Vermassen T, et al. (2026). Shaping next decade of systemic therapy for head and neck squamous cell carcinoma: where do we go next?. Frontiers in oncology, 16, 1799378. https://doi.org/10.3389/fonc.2026.1799378
MLA
Saerens M, et al.. "Shaping next decade of systemic therapy for head and neck squamous cell carcinoma: where do we go next?." Frontiers in oncology, vol. 16, 2026, pp. 1799378.
PMID
41971448 ↗
Abstract 한글 요약
Outcomes of patients with relapsed or metastatic head and neck squamous cell carcinoma (R/M HNSCC) remain poor, despite the widespread incorporation of immune checkpoint inhibitors into contemporary treatment algorithms. Although programmed death-1 (PD-1) blockade with pembrolizumab, administered either alone or in combination with chemotherapy, has become the cornerstone of first line therapy for patients with PD-L1 positive disease, durable clinical benefit is achieved in only a minority of cases. This narrative review explores the most promising systemic treatment strategies expected to shape the management of R/M HNSCC over the coming decade, including bispecific antibodies, HPV directed therapeutic vaccines, antibody-drug conjugates, and other emerging modalities. We discuss their underlying mechanisms of action, review clinical data from early phase studies, and highlight ongoing phase III trials with the potential to redefine future treatment paradigms in R/M HNSCC.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Newly Identified Transcriptomic Biomarkers and Gene Signature of Pathological Complete Response to Induction Chemoimmunotherapy in Locally Advanced Head and Neck Squamous Cell Carcinoma.
- Landscape of T-cell engagers in solid tumors.
- Multicenter real-world data on immunotherapy for R/M HNSCC from China: comprehensive analysis of efficacy and survival differences across diverse clinical backgrounds, and identification of predictive peripheral blood biomarkers.
- Role of Radiotherapy in the Era of Novel Immune-Based Treatment Strategies for Multiple Myeloma.
- Intraperitoneal Co-Delivery of Claudin18.2×41BB and EpCAM×CD3 Bispecific Antibodies via mRNA-LNPs Synergistically Suppresses Gastric Cancer Peritoneal Metastasis Through T Cell Co-Activation.
- Bispecific Antibodies Versus Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Comparative Narrative Review of Efficacy, Safety, and Accessibility.